Fosifloxuridine nafalbenamide is a Small Molecule owned by NuCana, and is involved in 4 clinical trials, of which 1 was completed, and 3 are ongoing.

Fosifloxuridine nafalbenamide (NUC-3373) is 5FU/FUDR ProTide. Fluorouracil and floxuridine complex interference with DNA synthesis and to a lesser extent, inhibition of RNA formation through the drug's incorporation into RNA, thus leading to the production of fraudulent RNA. Fluorouracil also inhibits uracil riboside phophorylase, which prevents the utilization of preformed uracil in RNA synthesis. As well, the monophosphate of floxuridine, 5-fluoro-2'-deoxyuridine-5'-phosphate (FUDR-MP) inhibits the enzyme thymidylate synthetase. This leads to the inhibition of methylation of deoxyuridylic acid to thymidylic acid, thus interfering with DNA synthesis.

The revenue for Fosifloxuridine nafalbenamide is expected to reach a total of $4.2bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Fosifloxuridine nafalbenamide NPV Report.

Fosifloxuridine nafalbenamide was originated by Cardiff University and is currently owned by NuCana.

Fosifloxuridine nafalbenamide Overview

Fosifloxuridine nafalbenamide (NUC-3373) is under development for the treatment of advanced solid tumors including colorectal cancer, breast cancer, cholangiocarcinoma, basal cell carcinoma, non-small cell lung cancer. The drug candidate consists of the active anti-cancer metabolite, FUDR-MP and a protective phosphoramidate moiety. It is a small molecule administered intravenously. The drug candidate is developed based on Protide technology platform.

NuCana Overview

NuCana, formerly NuCana BioMed, is a clinical-stage biopharmaceutical company. It focuses on developing novel and transformational medicines for cancer treatments. Its key products include Acelarin, which is in phase III clinical studies, and used to treat biliary tract cancer. The company is also developing products such as NUC-3373 and NUC-7738, which are under Phase I study and used to treat solid tumors. NuCana develops products based on the ProTide technology platform, which focuses on developing new generation, anti-cancer agents. The company markets its products in the UK and the US. NuCana is headquartered in Edinburgh, the UK.

The operating loss of the company was GBP47.9 million in FY2021, compared to an operating loss of GBP36.4 million in FY2020. The net loss of the company was GBP40.5 million in FY2021, compared to a net loss of GBP30.7 million in FY2020.

Quick View – Fosifloxuridine nafalbenamide

Report Segments
  • Innovator
Drug Name
  • Fosifloxuridine nafalbenamide
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Oncology
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.